Kyrgyzstan vs Somalia: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Kyrgyzstan
- Somalia
How they compare
Kyrgyzstan currently reports 473.11 deaths against 336.41 deaths in Somalia, a difference of 136.7 deaths.
That makes Kyrgyzstan's figure about 1.4 times Somalia's.
The two have swapped places 3 times across 33 shared years of data; in 1990 it was Somalia ahead.
Kyrgyzstan ranks 95th and Somalia ranks 98th of 157 countries.
Across the 4 decades both report, Kyrgyzstan averaged higher in 1 and Somalia in 2.
Head to head by decade
| Decade | Kyrgyzstan | Somalia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 6.55 deaths | 33.63 deaths | 27.08 deaths | Somalia |
| 2010s | 186.13 deaths | 264.05 deaths | 77.92 deaths | Somalia |
| 2020s | 377.71 deaths | 331.82 deaths | 45.89 deaths | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Kyrgyzstan or Somalia?
- Kyrgyzstan, at 473.11 deaths against 336.41 deaths in Somalia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Kyrgyzstan and Somalia?
- 136.7 deaths, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kyrgyzstan and Somalia?
- 33 years are reported by both, from 1990 to 2022.
- How do Kyrgyzstan and Somalia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Kyrgyzstan ranks 95th and Somalia ranks 98th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.